TheraRadar
← Back
Data updated: Jun 28, 2026

Ferring Pharmaceuticals Inc.

Biotech
OncologyImmunologyGastroenterology Execution: Excellent

Ferring Pharmaceuticals Inc. is a biotechnology company focused on Oncology, Immunology, Gastroenterology.

1974
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

Ferring Pharmaceuticals Inc. at a Glance

  • Strong track record with 84% execution quality across 129 trials
  • Fast trial execution (18 months median completion)

Ferring Pharmaceuticals Inc.'s Key Drugs

Ferring Pharmaceuticals Inc.'s core commercial portfolio centers on Rebyota, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.

Rebyota
Approved 2022

Ferring Pharmaceuticals Inc.'s Recent FDA Approvals

New NDA/BLA approvals for Ferring Pharmaceuticals Inc. over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

Ferring Pharmaceuticals Inc.'s Therapeutic Areas

Ferring Pharmaceuticals Inc.'s approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 57%
0 drugs Phase 3: 19 Phase 2: 2 Phase 1: 4
Immunology 23%
0 drugs Phase 3: 8 Phase 1: 2
Gastroenterology 15%
0 drugs Phase 3: 5 Phase 1: 2
Infectious Disease 3%
0 drugs Phase 3: 1
Metabolic 3%
0 drugs Phase 3: 1

Ferring Pharmaceuticals Inc. Pipeline Snapshot

Ferring Pharmaceuticals Inc. has 44 active clinical programs from ClinicalTrials.gov — 34 Phase 3, 2 Phase 2 and 8 Phase 1.

34
Phase 3
2
Phase 2
8
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Rebyota leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 62/72 completed
  • • Speed: 18 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges